OncoMatch/Clinical Trials/NCT07092566
R.E.C.K vs Exparel in Robotic Nephrectomy
Is NCT07092566 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for renal carcinoma.
Treatment: Ropivacaine HCL · Exparel · Epinephrine · Clonidine HCL · Ketorolac — The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Levine Cancer · Charlotte, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07092566 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages